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Sulfasalazine is a compound of 5-aminosalicylic acid (5-ASA) and sulfapyridine joined by an azo bond. It
is a widely used drug in the treatment of chronic inﬂammatory bowel disease. Fatal toxicity of sulfa-
salazine arises from its effects on the bone marrow and the resulting blood dyscrasias. Pulmonary
toxicity from sulfasalazine is a rather rare ﬁnding. Here, we present the case of a patient who developed
acute eosinophilic pneumonia with sulfasalazine use.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sulfasalazine is a compound of 5-aminosalicylic acid (5-ASA)
and sulfapyridine joined by an azo bond. It is a widely used drug in
the treatment of chronic inﬂammatory bowel disease. Fatal toxicity
of sulfasalazine arises from its effects on the bone marrow and the
resulting blood dyscrasias [1]. Pulmonary toxicity from sulfasala-
zine is a rather rare ﬁnding. Acute eosinophilic pneumonia is
characterized by the rapid accumulation of eosinophils in the lung
in response to allergens, inﬂammation or infection. Symptom onset
is usually rapid and can include dyspnoea, fever, cough and chest
pain. Cigarette smoke, drugs and occupational factors have been
shown to trigger acute eosinophilic pneumonia. Here, we report a
patient who developed acute eosinophilic pneumonia with sulfa-
salazine use. This resolved completely with sulfasalazine with-
drawal and treatment with oral corticosteroids.2. Case report
A 44-year old woman with a background of ulcerative colitis
presented to the Emergency Department with a 5-week history of
fever, cough, dyspnoea and weight loss. She had been onnchoalveolar Lavage; CRP, C-
F-a, Tumour necrosis factor
ory Medicine, Education &
Park, Dublin 4, Ireland.
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Ltd. This is an open access article uSulfasalazine for a 12-week period and Adalimumab, a tumour
necrosis factor-alpha (TNF-a) antagonist. Both medications were
held on admission. She was pyrexial (38.2 C), tachypnoeic (respi-
ratory rate of 20/min) with normal oxygen saturations on room air
(98%). Physical examination revealed scattered crepitation over
both lungs on auscultation. Blood tests showed a peripheral
eosinophilia (0.6  109/L) and a raised C-reactive protein (CRP). An
autoimmune screenwas negative. Chest radiograph (Fig. 1) showed
new, bilateral multilobar pulmonary inﬁltrates. Sputum culturewas
negative for pathogenic bacteria and acid-fast bacilli. A tuberculin-
skin test was negative. She proceeded to have to ﬁbreoptic bron-
choscopy that was unremarkable. Bronchoalveolar lavage (BAL)
(Fig. 2) was negative for infective aetiologies including viral,
tuberculous and fungal infections. However, the differential cell
count from the BAL showed 41% eosinophils. A diagnosis of
Sulfasalazine-induced eosinophilic pneumonia was made based on
our ﬁndings and a review of her medications. Oral corticosteroids
were started and she improved signiﬁcantly with gradual
improvement in her respiratory symptoms. After consultation with
the gastroenterologist, Adalimumab was restarted but the Sulfa-
salazine was discontinued. She was reviewed in the respiratory
clinic 2 weeks later. Her chest radiograph (Fig. 3) had dramatically
improved with near complete resolution of the bilateral pulmonary
inﬁltrates.3. Discussion
The sulfapyridine moiety in sulfasalazine, which acts as a carrier
to transport 5-ASA to the colon, is believed to be responsible fornder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest radiograph on admission.
Fig. 2. Bronchoalveolar lavage cytology showing eosinophils (MGG stain).
Fig. 3. Chest radiograph 2 weeks after treatment with oral corticosteroids.
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persensitivity reactions such as eosinophilic pneumonia, ﬁbrosing
alveolitis and bronchiolitis obliterans remain rare with use of sul-
fasalazine and are usually self-limiting. However there have been
case reports with fatal outcomes, particularly in cases where the
drug was not withdrawn [2,3]. We believe that sulfasalazine is theoffending drug in our patient despite the time lag between
commencing sulfasalazine and the onset of symptoms, as her
symptoms appeared after sulfasalazine was administered,
improved once sulfasalazine was discontinued and there are no
other alternative causes that could have caused the reaction.
Eosinophilic pneumonia should be considered in patients who
are on sulfasalazine treatment who present with pulmonary
symptoms and abnormal chest radiography, accompanied by pe-
ripheral eosinophilia. The symptom triad of dyspnoea, cough and
fever will occur in about 50% of cases [1]. BAL ﬁndings can support
the diagnosis but the absence of eosinophils in the lavage ﬂuid does
not out rule eosinophilic pneumonia. The pulmonary symptoms
mentioned above will resolve completely in a few weeks after
withdrawal of the drug in the majority of cases. Although the evi-
dence for corticosteroids in sulfasalazine induced lung toxicity is
weak, a trial of systemic steroid therapy can be considered if the
patient is very ill despite sulfasalazinewithdrawal. There have been
suggestions that a re-challenge or a provocation test is essential to
establish a temporal relation, however given the signiﬁcant
morbidity of eosinophilic pneumonia and the availability of alter-
native 5-ASA agents such as mesalazine and olsalazine [4] for
treatment of ulcerative colitis, we deemed this inadvisable in the
case of this patient.Conﬂict of interest
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